HenagliflozinAlternative Names: SHR-3824
Latest Information Update: 23 May 2017
Price : $50
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antihyperglycaemics; Glucosides
- Mechanism of Action Sodium-glucose transporter 2 inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Type 2 diabetes mellitus
Most Recent Events
- 22 May 2017 Jiangsu HengRui Medicine plans a phase III trial for Type-2 diabetes mellitus (Monotherapy) in China (NCT03159052)
- 15 Dec 2016 Biomarkers information updated
- 01 May 2015 Jiangsu HengRui Medicine Co. initiates enrolment in a phase I drug interaction trial in volunteers in China (NCT02500485)